3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
32
Myelodysplastic Syndromes
16
Leukemia, Myelomonocytic, Chronic
7
Recurrence
6
Neoplasms
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Leukemia
3
Leukemia, Myeloid
2
Carcinoma, Non-Small-Cell Lung
2
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Preleukemia
1
Polycythemia Vera
1
Pathologic Complete Response
1
Myeloproliferative Disorders
1
Melanoma
1
Malignant Solid Tumor
1
Hematologic Diseases
1
Carcinoma, Renal Cell
1
Bone Marrow Diseases
1
Blast Crisis
1
Advanced Breast Cancer
1
Interventions
sargramostim
2
Monatide (IMS 3015)
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Azacitidine
2
venetoclax
1
ruxolitinib
1
rucaparib
1
olaparib
1
cc-486
1
Pemetrexed
1
Observation
1
Nivolumab
1
Decitabine
1
Cytarabine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pathologic Complete Response
×
Decitabine
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled